Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
Prostate Cancer Prostatic Dis
; 2024 Jul 05.
Article
in En
| MEDLINE
| ID: mdl-38969791
ABSTRACT
BACKGROUND/OBJECTIVES:
Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes. SUBJECTS/METHODS:
A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.RESULTS:
Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.CONCLUSIONS:
Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Prostate Cancer Prostatic Dis
/
Prostate cancer and prostatic diseases
/
Prostate cancer prostatic dis
Journal subject:
ENDOCRINOLOGIA
/
NEOPLASIAS
/
UROLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: